Overview

  • Product name

    XL-880 (Foretinib), HGFR and VEGFR2 inhibitor
  • Description

    Potent ATP-competitive HGFR and VEGFR2 inhibitor
  • Biological description

    Potent ATP-competitive HGFR and VEGFR2 inhibitor (IC50 values are 0.4 and 0.9 nM for Met and KDR respectively). Blocks proliferation, induces anoikis and inhibits metastasis. Shows antitumor effects in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    849217-64-7
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Knubel KH  et al. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget 5:1338-51 (2014). Read more (PubMed: 24658326) »
  • Kataoka Y  et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 30:1352-60 (2012). Read more (PubMed: 21655918) »
  • Zillhardt M  et al. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 17:4042-51 (2011). Read more (PubMed: 21551255) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142022.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up